1 hour ago
1
Jonathan Kitchen
Superluminal Medicines, a healthcare company integrating AI/ML, announced partnership with Eli Lilly (NYSE:LLY) to advance small molecule therapeutics targeting cardiometabolic diseases and obesity.
Under the deal, Superluminal is eligible to receive up to $1.3B, which includes upfront and near-term payments, an equity investment, development and
English (US) ·